Retinoblastoma patients who are RB1 mutation carriers have been reported to have a higher chance of secondary cancers [51]; although there is limited evidence that chemotherapeutic agents lead to secondary cancer in retinoblastoma patients. This evidence concerns the gene RB1 and retinoblastoma.